JP2019534327A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534327A5 JP2019534327A5 JP2019545723A JP2019545723A JP2019534327A5 JP 2019534327 A5 JP2019534327 A5 JP 2019534327A5 JP 2019545723 A JP2019545723 A JP 2019545723A JP 2019545723 A JP2019545723 A JP 2019545723A JP 2019534327 A5 JP2019534327 A5 JP 2019534327A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutical composition
- dosage form
- disorder
- cns
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000015114 central nervous system disease Diseases 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 239000002552 dosage form Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 19
- 208000024827 Alzheimer disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 201000004810 Vascular dementia Diseases 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- 206010012289 Dementia Diseases 0.000 claims description 9
- 208000014094 Dystonic disease Diseases 0.000 claims description 8
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 8
- 208000023105 Huntington disease Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 208000010877 cognitive disease Diseases 0.000 claims description 6
- 208000010118 dystonia Diseases 0.000 claims description 6
- 208000020016 psychiatric disease Diseases 0.000 claims description 6
- 208000029560 autism spectrum disease Diseases 0.000 claims description 5
- 208000010482 CADASIL Diseases 0.000 claims description 4
- 208000033221 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 claims description 4
- 208000033935 Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy Diseases 0.000 claims description 4
- 208000012661 Dyskinesia Diseases 0.000 claims description 4
- 208000027534 Emotional disease Diseases 0.000 claims description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 208000016886 cerebral arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 claims description 4
- 229960004502 levodopa Drugs 0.000 claims description 4
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 230000009529 traumatic brain injury Effects 0.000 claims description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 206010065040 AIDS dementia complex Diseases 0.000 claims description 2
- 208000007848 Alcoholism Diseases 0.000 claims description 2
- 206010002329 Aneurysm Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 206010008096 Cerebral atrophy Diseases 0.000 claims description 2
- 208000027104 Chemotherapy-Related Cognitive Impairment Diseases 0.000 claims description 2
- 208000024254 Delusional disease Diseases 0.000 claims description 2
- 208000020401 Depressive disease Diseases 0.000 claims description 2
- 201000010374 Down Syndrome Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 206010021143 Hypoxia Diseases 0.000 claims description 2
- 208000019022 Mood disease Diseases 0.000 claims description 2
- 208000018526 Narcotic-Related disease Diseases 0.000 claims description 2
- 239000008896 Opium Substances 0.000 claims description 2
- 208000028361 Penetrating Head injury Diseases 0.000 claims description 2
- 206010036631 Presenile dementia Diseases 0.000 claims description 2
- 208000013200 Stress disease Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 206010044688 Trisomy 21 Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 201000007930 alcohol dependence Diseases 0.000 claims description 2
- 208000011142 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 Diseases 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 208000024825 childhood disintegrative disease Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 230000007954 hypoxia Effects 0.000 claims description 2
- 201000010901 lateral sclerosis Diseases 0.000 claims description 2
- 230000003340 mental effect Effects 0.000 claims description 2
- 230000036651 mood Effects 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 201000005040 opiate dependence Diseases 0.000 claims description 2
- 229960001027 opium Drugs 0.000 claims description 2
- 208000019906 panic disease Diseases 0.000 claims description 2
- 208000002851 paranoid schizophrenia Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 230000001568 sexual effect Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 201000009032 substance abuse Diseases 0.000 claims description 2
- 231100000736 substance abuse Toxicity 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims description 2
- 230000000946 synaptic effect Effects 0.000 claims description 2
- 230000003956 synaptic plasticity Effects 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- 230000008736 traumatic injury Effects 0.000 claims description 2
- 208000037820 vascular cognitive impairment Diseases 0.000 claims description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 208000036640 Asperger disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 208000027877 Disorders of Sex Development Diseases 0.000 claims 1
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims 1
- 206010071368 Psychological trauma Diseases 0.000 claims 1
- 206010049644 Williams syndrome Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 239000000021 stimulant Substances 0.000 description 3
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 206010050389 Cerebral ataxia Diseases 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitrogen oxide(NO) Natural products O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000012202 Pervasive developmental disease Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022126467A JP2022160605A (ja) | 2016-11-08 | 2022-08-08 | ｓＧＣ刺激薬による中枢神経系疾患の治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662419059P | 2016-11-08 | 2016-11-08 | |
| US62/419,059 | 2016-11-08 | ||
| PCT/US2017/060299 WO2018089328A1 (en) | 2016-11-08 | 2017-11-07 | Treatment of cns diseases with sgc stimulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022126467A Division JP2022160605A (ja) | 2016-11-08 | 2022-08-08 | ｓＧＣ刺激薬による中枢神経系疾患の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534327A JP2019534327A (ja) | 2019-11-28 |
| JP2019534327A5 true JP2019534327A5 (enExample) | 2020-12-17 |
| JP7150740B2 JP7150740B2 (ja) | 2022-10-11 |
Family
ID=60452769
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019545723A Active JP7150740B2 (ja) | 2016-11-08 | 2017-11-07 | ｓＧＣ刺激薬による中枢神経系疾患の治療 |
| JP2022126467A Pending JP2022160605A (ja) | 2016-11-08 | 2022-08-08 | ｓＧＣ刺激薬による中枢神経系疾患の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022126467A Pending JP2022160605A (ja) | 2016-11-08 | 2022-08-08 | ｓＧＣ刺激薬による中枢神経系疾患の治療 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US11690828B2 (enExample) |
| EP (1) | EP3538096B1 (enExample) |
| JP (2) | JP7150740B2 (enExample) |
| KR (1) | KR102475124B1 (enExample) |
| CN (1) | CN110267658B (enExample) |
| AU (2) | AU2017359018C1 (enExample) |
| BR (1) | BR112019009449A2 (enExample) |
| CA (1) | CA3042548A1 (enExample) |
| CL (1) | CL2019001256A1 (enExample) |
| EA (1) | EA201991147A1 (enExample) |
| ES (1) | ES2972711T3 (enExample) |
| IL (1) | IL266275B2 (enExample) |
| MA (1) | MA46752A (enExample) |
| MX (2) | MX2019005342A (enExample) |
| PH (1) | PH12019501016A1 (enExample) |
| SG (1) | SG10202104865UA (enExample) |
| TW (1) | TWI812601B (enExample) |
| WO (1) | WO2018089328A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017356887B2 (en) * | 2016-11-08 | 2022-06-30 | Cyclerion Therapeutics, Inc. | sGC stimulators |
| WO2019055859A1 (en) * | 2017-09-14 | 2019-03-21 | Ironwood Pharmaceuticals, Inc. | TREATMENT OF METABOLIC SYNDROME BY SGC STIMULATOR |
| US12220414B2 (en) | 2018-07-11 | 2025-02-11 | Tisento Therapeutics Inc. | Use of sGC stimulators for the treatment of mitochondrial disorders |
| WO2020150698A1 (en) * | 2019-01-18 | 2020-07-23 | The Johns Hopkins University | Prevention of anesthetic-induced neurocognitive dysfunction |
| CN114929207A (zh) * | 2019-12-05 | 2022-08-19 | 载度思生命科学有限公司 | 利奥西呱的调节释放型药物组合物 |
| WO2021158059A1 (ko) | 2020-02-07 | 2021-08-12 | 건국대학교 글로컬산학협력단 | 릴메니딘 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물 |
| CN112924573B (zh) * | 2021-01-21 | 2022-01-04 | 山东英盛生物技术有限公司 | 一种阿比多尔、利巴韦林、氯喹的hplc-ms/ms检测方法 |
| WO2022225902A1 (en) * | 2021-04-20 | 2022-10-27 | Cyclerion Therapeutics, Inc. | Treatment of cns diseases with sgc stimulators |
| CN117915917A (zh) * | 2021-04-20 | 2024-04-19 | 帝善多制药公司 | 使用sGC刺激剂的CNS疾病治疗 |
| EP4456897A4 (en) * | 2021-12-31 | 2025-12-10 | Tenax Therapeutics Inc | ORAL FORMULATIONS OF LEVOSIMENDAN FOR THE TREATMENT OF PULMONARY HYPERTENSION WITH HEART FAILURE AND PRESERVED EJECTION FRACTION |
| CN120752026A (zh) * | 2023-02-03 | 2025-10-03 | R·P·谢勒技术有限公司 | 渗透药用胶囊 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
| US4203440A (en) | 1978-10-23 | 1980-05-20 | Alza Corporation | Device having variable volume chamber for dispensing useful agent |
| US4627850A (en) | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
| DE3660408D1 (en) | 1985-02-27 | 1988-08-25 | Oerlikon Buehrle Ag | Apparatus for measuring the vibrations of a spiral bevel gear transmission in a gear-testing machine |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5324280A (en) | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| CZ302691B6 (cs) | 1998-07-08 | 2011-09-07 | Sanofi - Aventis Deutschland GmbH | N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi |
| DE19830430A1 (de) | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| DE69915346T2 (de) | 1998-12-17 | 2004-07-22 | Alza Corp., Mountain View | Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen |
| US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| CA2534371A1 (en) | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| DE102006020327A1 (de) * | 2006-04-27 | 2007-12-27 | Bayer Healthcare Ag | Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung |
| CN101939053A (zh) | 2007-09-06 | 2011-01-05 | 默沙东公司 | 可溶性的鸟苷酸环化酶活化剂 |
| CA2711134A1 (en) | 2008-01-24 | 2009-07-30 | Merck Sharp & Dohme Corp. | Angiotensin ii receptor antagonists |
| CA2743864A1 (en) | 2008-11-25 | 2010-06-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| CA2753434C (en) | 2009-02-26 | 2014-07-15 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| US9284301B2 (en) | 2010-03-25 | 2016-03-15 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| UA107112C2 (uk) | 2010-05-27 | 2014-11-25 | Мерк Шарп Енд Доме Корп. | Активатори розчинної гуанілатциклази |
| WO2012058132A1 (en) | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| KR20180094965A (ko) * | 2015-12-14 | 2018-08-24 | 아이언우드 파마슈티컬스, 인코포레이티드 | 위장 괄약근 기능장애의 치료를 위한 sGC 자극제의 용도 |
| WO2017108441A1 (en) | 2015-12-22 | 2017-06-29 | Universiteit Maastricht | Treatment of cognitive impairment with cgc stimulator |
| WO2017121700A1 (de) | 2016-01-15 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | 1,3-disubstituierte 1h-pyrazolo[3,4-b]pyridin- derivate und ihre verwendung als stimulatoren der löslichen guanylatcyclase |
| IL264955B (en) * | 2016-09-02 | 2022-06-01 | Ironwood Pharmaceuticals Inc | Fused bicyclic sgc stimulators |
-
2017
- 2017-11-07 EP EP17804374.1A patent/EP3538096B1/en active Active
- 2017-11-07 JP JP2019545723A patent/JP7150740B2/ja active Active
- 2017-11-07 CN CN201780080543.0A patent/CN110267658B/zh active Active
- 2017-11-07 TW TW106138467A patent/TWI812601B/zh active
- 2017-11-07 MX MX2019005342A patent/MX2019005342A/es unknown
- 2017-11-07 MA MA046752A patent/MA46752A/fr unknown
- 2017-11-07 CA CA3042548A patent/CA3042548A1/en active Pending
- 2017-11-07 IL IL266275A patent/IL266275B2/en unknown
- 2017-11-07 US US16/348,359 patent/US11690828B2/en active Active
- 2017-11-07 ES ES17804374T patent/ES2972711T3/es active Active
- 2017-11-07 KR KR1020197016351A patent/KR102475124B1/ko active Active
- 2017-11-07 SG SG10202104865UA patent/SG10202104865UA/en unknown
- 2017-11-07 AU AU2017359018A patent/AU2017359018C1/en active Active
- 2017-11-07 WO PCT/US2017/060299 patent/WO2018089328A1/en not_active Ceased
- 2017-11-07 EA EA201991147A patent/EA201991147A1/ru unknown
- 2017-11-07 BR BR112019009449A patent/BR112019009449A2/pt not_active IP Right Cessation
-
2019
- 2019-05-07 CL CL2019001256A patent/CL2019001256A1/es unknown
- 2019-05-07 MX MX2022010852A patent/MX2022010852A/es unknown
- 2019-05-08 PH PH12019501016A patent/PH12019501016A1/en unknown
-
2022
- 2022-08-08 JP JP2022126467A patent/JP2022160605A/ja active Pending
-
2023
- 2023-05-12 US US18/196,826 patent/US20230381153A1/en not_active Abandoned
- 2023-11-22 AU AU2023270267A patent/AU2023270267A1/en not_active Abandoned
-
2024
- 2024-07-31 US US18/790,576 patent/US20250108040A1/en not_active Abandoned
- 2024-12-18 US US18/986,454 patent/US20260000653A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004010787T2 (de) | 3-substitutierte-2(arylalkyl)-1-azabicycloalkane und methoden zu deren verwendung | |
| JP5657556B2 (ja) | α７選択的リガンドを用いる治療 | |
| Bourin et al. | Nicotinic receptors and Alzheimer's disease | |
| JP2022515766A5 (enExample) | ||
| JP2011528372A5 (enExample) | ||
| JP7794910B2 (ja) | Ｅａａｔ２活性化因子およびその使用方法 | |
| RS58279B1 (sr) | Jedinjenja 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-on i njihova upotreba kao negativni alosterički modulatori mglu2-receptora | |
| MX2007000669A (es) | Moduladores de receptores acetilcolina nicotinicos alfa 7 y sus usos terapeuticos. | |
| KR20190140968A (ko) | Vmat2 억제제 화합물 및 그의 조성물 | |
| JP2019517469A (ja) | ピプラドロールを用いる行動症候群の治療方法 | |
| US20210198218A1 (en) | Compounds for therapeutic use | |
| JP2005537297A (ja) | アルファ−７ｎａｃｈｒ活性を有する１ｈ−ピラゾールおよび１ｈ−ピロール−アザビシクロ化合物 | |
| JP2017523201A5 (enExample) | ||
| AU2021200512B2 (en) | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use | |
| AU2017301767A1 (en) | Compounds and compositions and uses thereof | |
| RU2016132574A (ru) | Органические соединения | |
| JP6810983B2 (ja) | （ｒ）−ジミラセタム（１）と（ｓ）−ジミラセタム（２）を非ラセミ比で含む相乗的組成物 | |
| JP2024511997A5 (enExample) | ||
| JP2004529936A5 (enExample) | ||
| JP2019535715A5 (enExample) | ||
| JP2010529080A5 (enExample) | ||
| JP2011520987A (ja) | ニューロンｎＡＣｈＲの無痛性脱感作剤およびその使用方法 | |
| KR102471059B1 (ko) | 장애의 치료를 위한 하이드록시노르케타민 유도체 | |
| CA3260032A1 (en) | COMPOSITIONS AND USES OF PSILOCYBINE AND PSILOCIN | |
| ZA201005203B (en) | Chromene compounds,a process for their preparation and pharmaceutical compositions containing them |